July 17 (Reuters) - Danish drugmaker Novo Nordisk said on Friday that India's drug regulator has approved its obesity drug Wegovy for the treatment of metabolic dysfunction-associated steatohepatitis ...

Add Yahoo as a preferred source to see more of our stories on Google. FILE PHOTO: FILE PHOTO: Boxes of Ozempic and Wegovy made by Novo Nordisk are seen at a pharmacy in London, Britain March 8, 2024.

Novo Nordisk's Wegovy approved in India for MASH, expanding beyond obesity. First GLP-1 for fatty liver disease, boosting market for Emcure.

Novo Nordisk said that Wegovy is the first and only GLP-1 receptor agonist (GLP-1 RA) approved globally and in India for the ...

Novo Nordisk - Read all the latest news headline updates on Novo Nordisk. Get all the Novo Nordisk breaking news updates, videos, photostories and more at Business Standard.

March 31 (Reuters) - Novo Nordisk (NOVOb.CO), opens new tab has again cut the prices of its blockbuster diabetes and weight-loss drugs Ozempic and Wegovy by up to 36% and 48% in India, to fend off ...

Novo Nordisk's pill costs less than the Wegovy shot and Foundayo, Lilly's GLP-1 tablet for weight loss The Wegovy pill has had one of the most successful drug launches of all time. At least 3 million ...

It's the latest move by Novo Nordisk to compete against Eli Lilly, which has dominated the GLP-1 market Novo Nordisk said its new high-dose version of the Wegovy injection is now available. Novo ...

Pharmaceutical companies have only begun to tap the potential demand for obesity treatments, and expanding access should be a top priority, said Mike Doustdar, the head of Novo Nordisk (NVO), the ...

Wegovy has just had its first weight-loss pill licensed for use in the UK to much fanfare. The GLP-1 medication was previously only available as an injection; the semaglutide tablets are expected to ...